世界の核医学/放射性医薬品市場...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 27)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. – 35)

3 Market Overview (Page No. – 40)
3.1 Introduction
3.2 Definition Of Radiopharmaceuticals
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand
For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts The Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.4.3.3 Cyclotron-Based Production
3.4.3.4 Neurological Applications
3.4.4 Threat
3.4.4.1 Japanese Reactors Inefficient To Compensate The Domestic Nuclear Demand
3.5 Winning Imperatives
3.5.1 Investments On New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu-Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Fukushima Nuclear Disaster
3.7 Opal – A Sustainable Solution For Global Crisis In Mo-99 Supply
3.8 Regulatory Affairs
3.8.1 Japan
3.8.1.1 The Pharmaceuticals And Medical Devices Agency (PMDA, Sogo-Kiko)
3.8.2 China
3.8.2.1 China Food And Drug Administration (CFDA) & Office Of Administrative Protection
For Pharmaceuticals(OOAP)
3.8.3 India
3.8.3.1 Board Of Radiation & Isotope Technology (BRIT)
3.8.4 South Korea
3.8.4.1 Korea Institute Of Nuclear Safety (KINS) And Korea Institute Of Nuclear Nonproliferation
And Control(KINAC)
3.8.5 Malaysia
3.8.5.1 Atomic Energy Licensing Board (AELB)
3.8.6 Indonesia
3.8.6.1 Nuclear Energy Regulatory Agency (BAPETEN)
3.8.7 Australia & New Zealand
3.8.7.1 The Australian And New Zealand Society Of Nuclear Medicine (ANZSNM)
3.8.8 Roa
3.8.8.1 Dost (Philippines) & Crpns (Singapore)
3.9 Market Share Analysis
3.9.1 Radiopharmaceuticals Market
3.9.2 Enriched Stable Isotope Market

4 Asia-Pacific Radiopharmaceuticals Market, By Isotope (Page No. – 61)
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Sustainable Supply Of Technetium
4.2.2.2 Thallium-201 (TL-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (GA-67)
4.2.2.3.1 Fluorine-18 (PET) Might Seize Ga-67 (SPECT) Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others
4.2.3 Positron-Emission Tomography (PET) Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 Fdg
4.2.3.1.2 Florbetapir
4.2.3.1.3 Factors Affecting Fluorine-18 Market
4.2.3.1.3.1 Rise In Pet Procedures Increases Demand For Fdg
4.2.3.1.3.2 High Generation Costs Of Fdg
4.2.3.1.3.3 Need For Speedy & Efficient Transportation
4.2.3.2 Rubidium-82 (RB-82)
4.2.3.3 Others
4.3 Therapeutic Isotopes
4.3.1 Opportunity Matrix
4.3.2 Beta Emitters
4.3.2.1 Iodine-131 (I-131)
4.3.2.2 Yttrium-90 (Y-90)
4.3.2.2.1 Y-90 Market Influenced By Popularity Of Nordion’s Therasphere
4.3.2.3 Samarium-153 (Sm-153)
4.3.2.4 Rhenium-186 (Re-186)
4.3.2.5 Lutetium-177 (LU-177)
4.3.2.5.1 LU-177 Is A Potential Treatment Option For Neuroendocrine Cancer
4.3.2.6 Others
4.3.2.6.1 RE-188 And P-33 Are Notable Promising Isotope
4.3.3 Alpha Emitters
4.3.3.1 Radium-223 (RA-223) & Alpharadin
4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone
Metastases From CRPC
4.3.3.1.2 First In-Class Alpha Pharmaceutical
4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
4.3.3.1.4 Success Of Alpharadin
4.3.3.1.5 Porter’s Five Forces Analysis
4.3.3.1.6 Swot Analysis
4.3.3.2 Actinium-225 (AC-225)
4.3.3.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
4.3.3.4 Astatine-211 (AT-211)
4.3.3.5 Radium-224 (RA-224)
4.3.3.6 Thorium-227 (TH-227)
4.3.4 Brachytherapy
4.3.4.1 Cesium-131
4.3.4.2 Iodine-125
4.3.4.3 Palladium-103
4.3.4.4 Iridium-192
4.3.4.5 Others

5 Asia-Pacific Radiopharmaceuticals Market, By Application/Indication (Page No. – 117)
5.1 Introduction
5.2 Diagnostic Application
5.2.1 Spect
5.2.1.1 Cardiology
5.2.1.2 Lymphoma
5.2.1.3 Thyroid
5.2.1.4 Neurology
5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Driving Growth Of The
Neurology Spect Market
5.2.1.5 Others
5.2.2 Pet
5.2.2.1 Oncology
5.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.4 Others
5.3 Therapeutic Application
5.3.1 Thyroid
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.4 Endocrine Tumors
5.3.5 Others

6 Asia-Pacific Enriched Stable Isotopes Market (Page No. – 145)
6.1 Introduction
6.2 Market Overview
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints
6.3.2.1 Harmful Effects Of High Doses Of Stable Isotopes Affect Market Growth
6.3.2.2 High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotope
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Application
6.5.1 Diagnostic & Therapy
6.5.2 Research
6.5.3 Pharmaceutical
6.5.4 Industrial Sector

7 Geographic Analysis (Page No. – 165)
7.1 Introduction
7.1.1 Apac Showcases Great Scope For Market Development
7.2 Japan
7.2.1 Pet Diagnosis Increased Dramatically After 2002
7.2.2 Japanese Nuclear Market Affected By Fukushima Catastrophe In 2011
7.3 China
7.3.1 Alternative Procedures Hinder Nuclear Medicine Market
7.4 India
7.4.1 Tc-99m And F-18 Fdg, The Most Prominent Radiopharmaceuticals
7.5 South Korea
7.5.1 Nuclear Medicines Market Gained Momentum After Mid-1990s
7.6 Malaysia
7.6.1 Nuclear Medicines Market Showcased A Significant Development During The Post 1970’s Era
7.6.2 Patients Migrating To Neighboring Countries For Nuclear Medicine Services
7.7 Indonesia
7.7.1 Lack Of Skilled Professionals Affects Indonesian Nuclear Medicines Market
7.8 Australia
7.8.1 The Opal Reactor Has The Capacity To Produce Almost Half The Global Tc-99m Demand
7.8.2 Uninterrupted Mo-99 Production By Opal To Boost Tc-99m Usage
7.9 New Zealand
7.9.1 Alternative Procedures Affect Nuclear Medicines Market
7.10 Rest Of Asia (Roa)

8 Competitive Landscape (Page No. – 222)
8.1 Introduction
8.2 Agreements, Partnerships, Collaborations & Joint Ventures
8.3 Products Launch
8.4 Expansions
8.5 Mergers & Acquisitions
8.6 Other Developments

9 Company Profiles (Page No. – 232)
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.5 Eczacibasi-Monrol
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Siemens Healthcare (Subsidiary Of Siemens AG)
9.14 Taiyo Nippon Sanso Corporation
9.15 Urenco Limited
9.16 Rotem Industries, Ltd., Inc.
9.17 Australian Nuclear Association And Technology Organization (ANSTO)
9.18 Board Of Radiation And Isotope Technology (BRIT)
9.19 Institute Of Atomic Energy Polatom Radioisotope Centre
9.20 Institute Of Isotopes Co., Ltd.
9.21 Institute Of Radioelement (IRE)